Facing a tepid Alzheimer’s market, Lilly looks to build ‘a sense of urgency’ to jumpstart sales of donanemab

On pa­per, Alzheimer’s dis­ease should be an un­com­pli­cat­ed mar­ket for drug­mak­ers. There are mil­lions of po­ten­tial pa­tients, who un­til re­cent­ly had no re­al op­tion for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.